aTYR PHARMA (ATYR) Receivables - Other (2019 - 2025)
aTYR PHARMA (ATYR) has disclosed Receivables - Other for 7 consecutive years, with $873000.0 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Other fell 49.71% year-over-year to $873000.0, compared with a TTM value of $873000.0 through Dec 2025, down 49.71%, and an annual FY2025 reading of $873000.0, down 49.71% over the prior year.
- Receivables - Other was $873000.0 for Q4 2025 at aTYR PHARMA, down from $1.0 million in the prior quarter.
- Across five years, Receivables - Other topped out at $11.8 million in Q4 2022 and bottomed at $89000.0 in Q1 2021.
- Average Receivables - Other over 5 years is $1.6 million, with a median of $1.0 million recorded in 2025.
- The sharpest move saw Receivables - Other tumbled 89.17% in 2021, then soared 2606.9% in 2022.
- Year by year, Receivables - Other stood at $435000.0 in 2021, then skyrocketed by 2606.9% to $11.8 million in 2022, then tumbled by 79.31% to $2.4 million in 2023, then dropped by 28.74% to $1.7 million in 2024, then tumbled by 49.71% to $873000.0 in 2025.
- Business Quant data shows Receivables - Other for ATYR at $873000.0 in Q4 2025, $1.0 million in Q3 2025, and $498000.0 in Q2 2025.